Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sophie Burbridge"'
Autor:
John Maher, S M Hobbs, May C I van Schalkwyk, Sjoukje J. C. van der Stegen, Sophie Burbridge, Carol Box, Scott Wilkie, Ana Parente Pereira, Suzanne A. Eccles, David M. Davies
Publikováno v:
Journal of Clinical Immunology. 32:1059-1070
Chimeric antigen receptor (CAR) engineered T-cells occupy an increasing niche in cancer immunotherapy. In this context, CAR-mediated CD3ζ signaling is sufficient to elicit cytotoxicity and interferon-γ production while the additional provision of C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8cfc60d8f5037d611eaa1b846736734
https://doi.org/10.1007/s10875-012-9689-9
https://doi.org/10.1007/s10875-012-9689-9
Autor:
Vincent Kao, David M. Davies, May C I van Schalkwyk, Sjoukje J. C. van der Stegen, Zhe Liu, Ana C. Parente-Pereira, Laura Chiapero-Stanke, Carol Box, Sophie Burbridge, George J. Delinassios, Leticia Bosshard-Carter, Suzanne A. Eccles, Julie Foster, John Maher, Scott Wilkie, Stephen J. Mather
Publikováno v:
Molecular Medicine. 18:565-576
Pharmacological targeting of individual ErbB receptors elicits antitumor activity, but is frequently compromised by resistance leading to therapeutic failure. Here, we describe an immunotherapeutic approach that exploits prevalent and fundamental mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215971d871bcc66da53cf529cf97402a
https://doi.org/10.2119/molmed.2011.00493
https://doi.org/10.2119/molmed.2011.00493
Autor:
Robert Michael Goldstein, Declan Cahill, Charles Hanley, Jonathan D.H. Morris, John Maher, Ashish Chandra, Sophie Burbridge, Peter Harper, Simon Chowdhury
Publikováno v:
Cancers, Vol 3, Iss 4, Pp 4281-4293 (2011)
Cancers
Cancers; Volume 3; Issue 4; Pages: 4281-4293
Cancers
Cancers; Volume 3; Issue 4; Pages: 4281-4293
Prostate cancer is the most common cancer in men, both in the USA and Europe. Although incurable, metastatic disease can often be controlled for years with anti-androgen therapy. Once the disease becomes castrate resistant, the median survival is 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b71f13a7742ccbe2c982bf8d06e88b13
https://doi.org/10.3390/cancers3044281
https://doi.org/10.3390/cancers3044281
Autor:
John Maher, Ana Parente Pereira, Sjoukje J. C. van der Stegen, Sophie Burbridge, Siobhán Cleary, James Spicer, David M. Davies, Laura Chiapero-Stanke, Scott Wilkie
Publikováno v:
Journal of Biological Chemistry. 285:25538-25544
Polyclonal T-cells can be directed against cancer using transmembrane fusion molecules known as chimeric antigen receptors (CARs). Although preclinical studies have provided encouragement, pioneering clinical trials using CAR-based immunotherapy have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c23f2871542fe48a6715107bb03a3cef
https://doi.org/10.1074/jbc.m110.127951
https://doi.org/10.1074/jbc.m110.127951
Autor:
D. Ellison, David M. Davies, Julie Foster, John Maher, Sophie Burbridge, Stephen J. Mather, Jerome Burnet, Scott Wilkie, Sjoukje J. C. van der Stegen, Ana C. Parente-Pereira, Laura Chiapero-Stanke
Publikováno v:
Journal of clinical immunology. 31(4)
Adoptive immunotherapy using chimeric antigen receptor-engrafted T cells is a promising emerging therapy for cancer. Prior to clinical testing, it is mandatory to evaluate human therapeutic cell products in meaningful in vivo pre-clinical models. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3f8d469eca0ddf212e327f049a4a27c
https://pubmed.ncbi.nlm.nih.gov/21505816
https://pubmed.ncbi.nlm.nih.gov/21505816
Publikováno v:
Journal of Clinical Oncology. 30:212-212
212 Background: Infiltrating immune cells have been implicated in prostate carcinogenesis. Murine studies suggest that B-cell-derived lymphotoxin (LT)a may be a key effector in the evolution to castrate-resistant prostate cancer (CRPC) (Ammirante et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b9cb5b3aea0d3b53626dcbe737c3715
https://doi.org/10.1200/jco.2012.30.5_suppl.212
https://doi.org/10.1200/jco.2012.30.5_suppl.212
Autor:
Simon M. Hughes, Peter Harper, S. Chowdhury, L. Drudge-Coates, Sophie Burbridge, Gordon Kooiman, Declan Cahill, Janette Kinsella, Kiruthikah Thillai, C. Tang, A. Garcia-Imhof, S. Rudman
Publikováno v:
Journal of Clinical Oncology. 29:e15099-e15099
e15099 Background: Prostate cancer is the most common male cancer. Androgen deprivation therapy (ADT) is the mainstay of treatment for metastatic disease, and is increasingly used in radical therapy. Treatment with ADT causes bone mineral density (BM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df1bc8d384fdef9abbb57d0203efb2c2
https://doi.org/10.1200/jco.2011.29.15_suppl.e15099
https://doi.org/10.1200/jco.2011.29.15_suppl.e15099
Autor:
Sophie Burbridge, George J. Delinassios, Scott Wilkie, David M. Davies, Suzanne A. Eccles, Stephen J. Mather, Julie Foster, John Maher, Laura Chiapero-Stanke
Publikováno v:
Cancer Research. 70:1932-1932
Over-expression of the epidermal growth factor receptor (ErbB1) is found in the majority of squamous cell carcinomas of the head and neck (SCCHN), making it an attractive therapeutic target. However, tumors often become refractory to ErbB1-specific t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::747d1bbd46073a9ec2a4c1b7c4019b06
https://doi.org/10.1158/1538-7445.am10-1932
https://doi.org/10.1158/1538-7445.am10-1932
Autor:
Scott Wilkie, James Spicer, Laura Chiapero-Stanke, John Maher, David M. Davies, Sophie Burbridge
Publikováno v:
Molecular Cancer Therapeutics. 8:C242-C242
Introduction: Prostate cancer is the most common cancer in men. Standard therapy incorporates surgery, radiotherapy, anti-androgen therapy and chemotherapy. Once anti-androgen resistance occurs, median survival is only 18 months. Consequently, there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::710127612af435938ba6242c34151d88
https://doi.org/10.1158/1535-7163.targ-09-c242
https://doi.org/10.1158/1535-7163.targ-09-c242